Cancer

A Guide to Great Skin at Any Age

MISSION, Kan., March 17, 2025 /PRNewswire/ -- (Family Features) Here's the secret for achieving a glowing complexion: there is no…

9 months ago

Baird Medical’s AI Tumor Ablation Surgical Robot Wins “Most Valuable Investment Award,” Pioneering AI and Robotics Integration in Healthcare

NEW YORK, March 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company") has been…

9 months ago

IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals

CAMBRIDGE, United Kingdom, March 17, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals…

9 months ago

PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer

Press release PEP-Therapy receives FDA Orphan Drug Designation for PEP-010for treatment of Pancreatic Cancer Paris (France), March 17, 2025 –…

9 months ago

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable…

9 months ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an…

9 months ago

Lirum Therapeutics Announces Debut of LX-101 Results in Thyroid Eye Disease, Selected for Presentation at the 2025 NANOS Annual Meeting

New York, NY, March 17, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on…

9 months ago

Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new…

9 months ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types…

9 months ago

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

     The Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in…

9 months ago